Cargando…
The next generation of immunotherapy: keeping lung cancer in check
Lung cancer is the deadliest malignancy with more cancer deaths per year than the next three cancers combined. Despite remarkable advances in targeted therapy, advanced lung cancer patients have not experienced a significant improvement in mortality. Lung cancer has been shown to be immunogenic and...
Autores principales: | Somasundaram, Ashwin, Burns, Timothy F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402056/ https://www.ncbi.nlm.nih.gov/pubmed/28434399 http://dx.doi.org/10.1186/s13045-017-0456-5 |
Ejemplares similares
-
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
por: Ackley, James, et al.
Publicado: (2021) -
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Somasundaram, Ashwin, et al.
Publicado: (2017) -
Keeping carbon dioxide in check
por: Garcia, Alfredo J, et al.
Publicado: (2017) -
BCC or not: Sufu keeps it in check
por: Yin, Wen-Chi, et al.
Publicado: (2015) -
Mind the gap: Keeping UV lesions in check
por: Novarina, Daniele, et al.
Publicado: (2011)